NCT04716452 - Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

October 1, 2027

Conditions

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryRefractory/Relapse Acute Myeloid Leukemia

Interventions

DRUG

Ceramide NanoLiposome (Ceraxa)

Ceramide NanoLiposome will be given by IV twice a week. The dose, which is based on body size, will be increased for the next group of patients if the first group of patients tolerates that dose and it will decrease for the next group if they do not tolerate the dose.

Trial Locations (1)

22903

University of Virginia Cancer Center, Charlottesville